Literature DB >> 33230204

Behavioral, neuroanatomical, and molecular correlates of resilience and susceptibility to maternal immune activation.

Flavia S Mueller1, Joseph Scarborough1, Sina M Schalbetter1, Juliet Richetto1,2, Eugene Kim3, Amalie Couch4, Yohan Yee5, Jason P Lerch5,6,7, Anthony C Vernon4,8, Ulrike Weber-Stadlbauer1,2, Urs Meyer9,10.   

Abstract

Infectious or noninfectious maternal immune activation (MIA) is an environmental risk factor for psychiatric and neurological disorders with neurodevelopmental etiologies. Whilst there is increasing evidence for significant health consequences, the effects of MIA on the offspring appear to be variable. Here, we aimed to identify and characterize subgroups of isogenic mouse offspring exposed to identical MIA, which was induced in C57BL6/N mice by administration of the viral mimetic, poly(I:C), on gestation day 12. Cluster analysis of behavioral data obtained from a first cohort containing >150 MIA and control offspring revealed that MIA offspring could be stratified into distinct subgroups that were characterized by the presence or absence of multiple behavioral dysfunctions. The two subgroups also differed in terms of their transcriptional profiles in cortical and subcortical brain regions and brain networks of structural covariance, as measured by ex vivo structural magnetic resonance imaging (MRI). In a second, independent cohort containing 50 MIA and control offspring, we identified a subgroup of MIA offspring that displayed elevated peripheral production of innate inflammatory cytokines, including IL-1β, IL-6, and TNF-α, in adulthood. This subgroup also showed significant impairments in social approach behavior and sensorimotor gating, whereas MIA offspring with a low inflammatory cytokine status did not. Taken together, our results highlight the existence of subgroups of MIA-exposed offspring that show dissociable behavioral, transcriptional, brain network, and immunological profiles even under conditions of genetic homogeneity. These data have relevance for advancing our understanding of the variable neurodevelopmental effects induced by MIA and for biomarker-guided approaches in preclinical psychiatric research.

Entities:  

Mesh:

Year:  2020        PMID: 33230204      PMCID: PMC7850974          DOI: 10.1038/s41380-020-00952-8

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  59 in total

Review 1.  The environment and susceptibility to schizophrenia.

Authors:  Alan S Brown
Journal:  Prog Neurobiol       Date:  2010-10-16       Impact factor: 11.685

Review 2.  Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia.

Authors:  Urs Meyer; Joram Feldon; Manfred Schedlowski; Benjamin K Yee
Journal:  Neurosci Biobehav Rev       Date:  2005       Impact factor: 8.989

3.  Long-term Risk of Neuropsychiatric Disease After Exposure to Infection In Utero.

Authors:  Benjamin J S Al-Haddad; Bo Jacobsson; Shilpi Chabra; Dominika Modzelewska; Erin M Olson; Raphael Bernier; Daniel A Enquobahrie; Henrik Hagberg; Svante Östling; Lakshmi Rajagopal; Kristina M Adams Waldorf; Verena Sengpiel
Journal:  JAMA Psychiatry       Date:  2019-06-01       Impact factor: 21.596

4.  Autism after infection, febrile episodes, and antibiotic use during pregnancy: an exploratory study.

Authors:  Hjördis Ósk Atladóttir; Tine Brink Henriksen; Diana E Schendel; Erik T Parner
Journal:  Pediatrics       Date:  2012-11-12       Impact factor: 7.124

Review 5.  Developmental neuroinflammation and schizophrenia.

Authors:  Urs Meyer
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-11-15       Impact factor: 5.067

6.  Mouse models of maternal immune activation: Mind your caging system!

Authors:  Flavia S Mueller; Marcello Polesel; Juliet Richetto; Urs Meyer; Ulrike Weber-Stadlbauer
Journal:  Brain Behav Immun       Date:  2018-07-17       Impact factor: 7.217

7.  Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8.

Authors:  Lauren M Ellman; Raymond F Deicken; Sophia Vinogradov; William S Kremen; John H Poole; David M Kern; Wei Yann Tsai; Catherine A Schaefer; Alan S Brown
Journal:  Schizophr Res       Date:  2010-06-09       Impact factor: 4.939

Review 8.  Neurodevelopmental Resilience and Susceptibility to Maternal Immune Activation.

Authors:  Urs Meyer
Journal:  Trends Neurosci       Date:  2019-09-04       Impact factor: 13.837

Review 9.  Epigenetic and transgenerational mechanisms in infection-mediated neurodevelopmental disorders.

Authors:  U Weber-Stadlbauer
Journal:  Transl Psychiatry       Date:  2017-05-02       Impact factor: 6.222

10.  Prenatal fever and autism risk.

Authors:  M Hornig; M A Bresnahan; X Che; A F Schultz; J E Ukaigwe; M L Eddy; D Hirtz; N Gunnes; K K Lie; P Magnus; S Mjaaland; T Reichborn-Kjennerud; S Schjølberg; A-S Øyen; B Levin; E S Susser; C Stoltenberg; W I Lipkin
Journal:  Mol Psychiatry       Date:  2017-06-13       Impact factor: 15.992

View more
  24 in total

1.  Epigenetic signature of exposure to maternal Trypanosoma cruzi infection in cord blood cells from uninfected newborns.

Authors:  Hans Desale; Pierre Buekens; Jackeline Alger; Maria Luisa Cafferata; Emily Wheeler Harville; Claudia Herrera; Carine Truyens; Eric Dumonteil
Journal:  Epigenomics       Date:  2022-08-29       Impact factor: 4.357

Review 2.  Advantages and Limitations of Animal Schizophrenia Models.

Authors:  Magdalena Białoń; Agnieszka Wąsik
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

3.  Interaction of maternal immune activation and genetic interneuronal inhibition.

Authors:  Allison Anderson; Thiago C Genaro-Mattos; Luke B Allen; Katalin Koczok; Zeljka Korade; Karoly Mirnics
Journal:  Brain Res       Date:  2021-02-15       Impact factor: 3.252

4.  The relationship between the plasma proinflammatory cytokine levels of depressed/anxious children and their parents.

Authors:  Tomer Mevorach; Michal Taler; Shira Dar; Maya Lebow; Irit Schorr Sapir; Ron Rotkopf; Alan Apter; Silvana Fennig; Alon Chen; Abraham Weizman; Maya Amitai
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

5.  Symptomatic and preventive effects of the novel phosphodiesterase-9 inhibitor BI 409306 in an immune-mediated model of neurodevelopmental disorders.

Authors:  Joseph Scarborough; Daniele Mattei; Cornelia Dorner-Ciossek; Michael Sand; Roberto Arban; Holger Rosenbrock; Juliet Richetto; Urs Meyer
Journal:  Neuropsychopharmacology       Date:  2021-05-03       Impact factor: 7.853

6.  Mouse models of immune dysfunction: their neuroanatomical differences reflect their anxiety-behavioural phenotype.

Authors:  Darren J Fernandes; Shoshana Spring; Mark R Palmert; Jason P Lerch; Christina Corre; Andrew Tu; Lily R Qiu; Christopher Hammill; Dulcie A Vousden; T Leigh Spencer Noakes; Brian J Nieman; Dawn M E Bowdish; Jane A Foster
Journal:  Mol Psychiatry       Date:  2022-04-14       Impact factor: 13.437

7.  A schizophrenia subgroup with elevated inflammation displays reduced microglia, increased peripheral immune cell and altered neurogenesis marker gene expression in the subependymal zone.

Authors:  Hayley F North; Christin Weissleder; Janice M Fullerton; Rachel Sager; Maree J Webster; Cynthia Shannon Weickert
Journal:  Transl Psychiatry       Date:  2021-12-15       Impact factor: 6.222

Review 8.  Developmental Stressors Induce Innate Immune Memory in Microglia and Contribute to Disease Risk.

Authors:  Elisa Carloni; Adriana Ramos; Lindsay N Hayes
Journal:  Int J Mol Sci       Date:  2021-12-02       Impact factor: 5.923

Review 9.  Maternal immune activation and neuroinflammation in human neurodevelopmental disorders.

Authors:  Velda X Han; Shrujna Patel; Hannah F Jones; Russell C Dale
Journal:  Nat Rev Neurol       Date:  2021-08-02       Impact factor: 42.937

10.  Maternal immune activation as a risk factor for psychiatric illness in the context of the SARS-CoV-2 pandemic.

Authors:  Brittney Lins
Journal:  Brain Behav Immun Health       Date:  2021-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.